IBSA is proud to announce its presence at the Prix Galien 2021 edition, with an innovative formulation that combines hyaluronic acid and biotechnological chondroitin in the osteo-articular field.
The Prix Galien, established in France in 1970, has been present in Italy since 1992 and is the most prestigious international competition at the pharmaceutical level. The award aims to promote and reward the most significant and innovative advances and products in the healthcare sector. Over the years it has acquired more and more relevance among institutions and professionals.
IBSA, one of the world leaders in the production of hyaluronic acid that manages the entire product supply chain, from production to finished product, is about to launch a new formulation of hyaluronic acid and chondroitin, both made via bio-fermentation through IBSA patented processes rather than animal extraction.